612
Views
6
CrossRef citations to date
0
Altmetric
Original Articles

Tolerability and toxicity of pegaspargase in adults 40 years and older with acute lymphoblastic leukemia

ORCID Icon, , , , , , , ORCID Icon & show all
Pages 176-184 | Received 30 Apr 2020, Accepted 05 Sep 2020, Published online: 26 Sep 2020

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Krishna R Juluri, Chloe Siu & Ryan D Cassaday. (2022) Asparaginase in the Treatment of Acute Lymphoblastic Leukemia in Adults: Current Evidence and Place in Therapy. Blood and Lymphatic Cancer: Targets and Therapy 12, pages 55-79.
Read now
Benjamin J. Lee, Jean Doh, Alexandre Chan, Deepa Jeyakumar & Susan O’Brien. (2022) Increased incidence of Pegaspargase-induced hypertriglyceridemia and associated pancreatitis observed in the Hispanic adult patient population. Leukemia & Lymphoma 63:12, pages 2992-2995.
Read now

Articles from other publishers (4)

Benjamin J. Lee, Shawn P. Griffin, Jean Doh, Alexandre Chan, Stefan O. Ciurea, Deepa Jeyakumar, Angela G. Fleischman, Kiran Naqvi, Nicholas R. Pannunzio, Susan O’Brien & Piyanuch Kongtim. (2023) HyperCVAD versus pegaspargase‐containing regimens for Hispanic adults with newly diagnosed B ‐cell acute lymphoblastic leukemia . European Journal of Haematology.
Crossref
Taylor D. Coe-Eisenberg, Anthony J. Perissinotti, Bernard L. Marini, Kristen M. Pettit, Dale L. Bixby, Patrick W. Burke & Lydia Benitez. (2023) Evaluating the efficacy and toxicity of dose adjusted pegylated L-asparaginase in combination with therapeutic drug monitoring. Annals of Hematology.
Crossref
Christina Lee, Thomas M Leventhal & Chimaobi M Anugwom. (2021) L-Asparaginase-Induced Hepatotoxicity Treated Successfully With L-Carnitine and Vitamin B Infusion. Cureus.
Crossref
David O. Riley, Jenna M. Schlefman, Hans Christoph Vitzthum Von Eckstaedt V, Amy L. Morris, Michael K. Keng & Firas El Chaer. (2021) Pegaspargase in Practice: Minimizing Toxicity, Maximizing Benefit. Current Hematologic Malignancy Reports 16:3, pages 314-324.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.